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Impact of the Human Genome Project
at the Interface between Patent and FDA Laws
Brian C. Cunningham*
Biotechnology is nothing new, exceptfor lauyers.1

The Technology
The Human Genome Project (Project) is an international effort to
complete the sequencing of the 100,000 genes that comprise the human
genome. Upon conclusion of the Project, estimated to occur around the
year 2005 and much sooner than many realize, the genes responsible for
single gene deficiency diseases, e.g., Huntington's disease and cystic
fibrosis, as well as for multifactorial diseases, e.g., atherosclerosis and
cancer, will have been identified. 2 The Project seems almost like
science fiction: It is easy to think of it as not having immediate policy
implications. Yet, as the Project's conclusion nears, there is little time to
struggle with issues that will be raised.
The Project's progress has been matched by developments in
techniques for performing human gene therapy. The first protocol was
approved by the Recombinant Advisory Committee of the National
Institutes of Health (RAC) in 1990. Since then, more than 200 people,
in about a dozen countries, have been treated in Phase I and II clinical
trials with no major side effects. 3 Also, Merck has established a gene
therapy division. 4 Dr. Philip Noguchi, in charge of U.S. Food and
Drug Administration (FDA) regulation of biotech products, says:
"What we've seen so far is almost trivial compared to what's
*
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Testimony of Dr. Nelson A. Wivel before the House Committee on Science,

Space & Technology, Sept. 29, 1994, at 89.
3 Genesis Group Associates, Inc., An Overview of Gene Therapy (Feb 1995).
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coming ....
" 5 He added that the results thus far are so good that the
6
FDA expects to see gene therapies on the market within a few years.
Although information gained from the Project will find application
in many fields, 7 the combination of that information with techniques
for performing germ line cell gene therapy (collectively, genome
technology)8 is particularly noteworthy. In my judgment, the ability
to alter the human genome for future generations, with the ability to
transfer characteristics between species, will raise ethical, moral and
legal issues as profound and troublesome as any faced by mankind thus
far. At the same time, it is likely that tomorrow's results of today's
research will be so far different from what we expect that our best
efforts to develop policy and law will be largely confounded.
The Interface
Patent and FDA law may be said to "interface" in a couple of
9
different ways. Legislative enactments such as the Orphan Drug Act
and the Patent Term Restoration Act 10 "interface" in the sense that
each modifies patent law and FDA law. However, a different kind of
interface may be found in the tension between the differing policies
which underlie patent and FDA law. The patent system is intended to
foster technological innovation and economic progress. FDA law serves
different policy objectives because it is intended to protect the public's
safety and welfare. To speak of the interface between patent law and
FDA law is to speak of balancing competing policy considerations.
While still a Congressman, Al Gore identified the tension between
11
patent and FDA law when he stated:
5 Lauren Neergard,
U.S. Government to Streamline Gene Therapy Oversight
1995).
(A.P. May 24,
6 Id.
7 The first full DNA sequences of free-living organisms, two bacteria, have been
determined which demonstrate the feasibility of sequencing the entire genome of
ever-more complicated organisms. Dr. Craig Ventor said recently that his Institute
for Genomic Research can now sequence ten or more microbial genome per year. See
Genesis, supra note 2.
8 The term, "germ line cell gene therapy," refers to the application of gene therapy
techniques to cells which are involved with reproduction, i.e. eggs and sperm.
9 21 U.S.C. § 360aa-ee
10 35 U.S.C. § 155A.
11 Senator Al Gore, Planning a New Biotechnology Policy, 5 Harv. J. Law & Tech.
19 (1991).
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The debate over biotechnology policy is at heart a debate
over information policy. At one level, the debate covers how
to provide intellectual property protection to the tools of
biotechnology and the valuable information they produce,
such as gene sequences and chromosome maps. At a
different level, the debate shifts to questions of how best to
distribute information to empower others and to prevent
information misuses and loss of privacy. Aided by the new
tools of the computer age, biotechnology is developing
faster than any previous technology. In the process of
development, biotechnology is creating a wider gap between
practice and policy. Our growing ability to transform
genetic information into new roducts and organisms is
intended to enhance agriculture, fight pollution, and alter
hereditary diseases which makes biotechnology a powerful,
and threatening tool.
Development of genome technology will outpace needed public
policy which will be required to cope with consequences. According to
Mr. Gore, "From the printing press to the atomic bomb, human kind
reveals a penchant to pioneer first and plan later. It is a simple truth that
technology develops faster and further than policy." 12 No matter how
safe and well controlled technology may be, public opinion will be
driven by lack of knowledge, lack of trust of science and government
and a tendency to believe that things are worse than what the public is
told. Therefore, the question is: How does society ensure that its
governmental and social institutions manage the future course of
evolution with enough wisdom to avoid catastrophic mistakes?
The real risk of genome technology is not whether appropriate
clinical trials can be designed, nor how or where inserted DNA
integrates into the host cell or any other such events. The real risk may
be illustrated by recalling the incident which led to the Asylomar
Conference and creation of the NIH's Guidelines for Research
Involving Recombinant DNA Molecules (Guidelines). 1 3 In 1971 Dr.
Paul Berg, then at Stanford University, now a Nobel Laureate, was
planning an experiment which involved the transfer of DNA from an
animal tumor virus to a virus which can infect E Coli, a common
human intestinal bacteria. Robert Polack, a researcher, heard about the
12
13

Id.
48 Fed. Reg. 24556 (1983).
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proposed experiment and advised Berg that if the new virus were to
escape from the laboratory it might survive in human intestinal bacteria,
exposing humans to a tumor-causing DNA which might even result in a
cancer epidemic. After months of soul searching, Dr. Berg finally
14
decided not to conduct hi" experiment.
This reminds us that no matter how well controlled and safe
experiments are, the unexpected may happen. If it does, consequences
could cause public opinion to galvanize to make further research more
difficult. Another serious incident is the now infamous rooftop
experiments a company conducted with an engineered bacterium on
trees on its roof without first obtaining regulatory approval. Of this,
Mr. Gore said, "The injury to the industry far exceeded any possible
injury to the environment. Not only was good risk assessment missing,
but so were candor, judgment, and perception." 15 Dr. French
Anderson recently well summarized public concern by saying, "[T]he
vast majority of people still do not know what genetic engineering is all
about and they are frightened by it. I do know what genetic
16
engineering is all about and I am frightened by it."
The Difficulty of Setting Policy
It is not easy to establish policy that deals with implications of
genome technology; value systems, risk tolerance levels and capacity for
understanding technology all vary widely. Neither public debate nor
the existing regulatory apparatus is well suited to resolving differences
that emerge from the moral and social plurality in the U.S. In 1984, the
17
Office of Technology Assessment reported:
There is little reason to believe that differences in opinion
about the appropriateness of human gene therapy will
resolve spontaneously, or even after extensive public
discussion. Where there is no agreement on what decision to
make, the only alternative is a process for making the
decision. Government agencies must demonstrate that the
process is rational and fair. (Emphasis added)
14 See Comment, supra note 1 at 897.
15 See Gore, supra note 10 at 22.
16 Dr. W. French Anderson, Editorial- Big Changes at the RAC! 5 Human Gene
Therapy 1309 (1994).
17 U.S. Congress, Office of Technology Assessment, Human Gene Therapy - A
Background Paper, at 30 (1984).
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Whatever process is adopted must involve professionals from many
disciplines, must be open to the public and must be insulated from
political pressures.
The best hope of setting policy to deal with the implications of
genome technology is to use an effective process for gathering necessary
information and subjecting that information to appropriate and
thorough consideration to formulate recommendations for appropriate
bodies. The following examination of processes currently used by
industry and government reveals that a new process will be required.
Industry DecisionProcess

By chance I have played a significant role in some important events
in biotechnology that have been most criticized. In 1980 and 1981,
while employed in-house, I represented Monsanto in its negotiations
with Genentech for a license to develop and sell bovine growth
hormone (BGH). Approved for administration to dairy cattle to
promote increased milk production, BGH has caused considerable
controversy and opposition. Some groups claim that milk from cows to
which it is administered is unsafe notwithstanding regulatory approval.
Others argue that the cost of BGH will further disadvantage small
farmers who cannot afford it. According to Al Gore, "These early
product choices indicate that little thought was given to which initial
18
products would increase confidence in biotechnology."
In the mid-80's, as General Counsel of Genentech, I was responsible
for directing that company's lobbying. I helped formulate and
implement a plan to respond to the potential additional regulation of
biotechnology and the Environmental Protection Agency's announced
intention to regulate biotechnology under the Toxic Substances and
Control Act. 19 The company was concerned that additional regulation
might impose unnecessary and costly burdens at a time when it was still
struggling to reach the market with its first products. Consequently,
Genentech effectively made the argument that prior to implementing
new regulations, agencies ought, to gather more information from
affected companies and thoroughly reconsider their roles. According to
Mr. Gore, "Political interference in agency decision-making effectively
18
19

Gore, supra note 11 at 25-26.
15 U.S.C. % 2601-2629.
7 Risk. Health, Safety & Environment 253 [Summer 1996]

prevented the 1986 Coordinated Framework from laying a clear path
20
from the lab to the marketplace."
While General Counsel of Genentech, I participated in decisions
that led to FDA's being sued to try to prevent it from giving market
approval for a competitor's product in contravention of a period of
exclusivity awarded to Genentech under the Orphan Drug Act for its
22
first product. 2 1 As to this, Mr. Gore said:
Early legal decisions have focussed on the debate over
technology and the right to exercise it experimentally.
Future legal debates wilt be over the policies to implement
the technology....
These roles have afforded a detailed view of processes by which
corporate America, large and small, makes choices and sets policies.
Corporate officers and employees are as caring and sensitive as
average Americans. They have families and personal concerns. Yet, they
work for organizations that expect loyalty to their objectives - ones
driven to a large extent by financial markets. Anyone who tries to
depart from corporate objectives by favoring social values over financial
goals is apt to be labeled "not a team player" and reminded that such a
course will likely to negatively affect the company's stock price. The
assumption is that stock price is paramount.
Indeed, stock prices often appear to be of paramount importance to
shareholders, financial analysts and the financial press. Although not
totally ignoring social concerns and policies, corporate decision makers
do tend to act to maximize corporate financial goals rather than to
advocate the point of view of society at large. They expect, perhaps
need, others to do so. Whether such corporate behavior is good or bad
does not matter because that behavior is not likely to change. "Others,"
whomever they are, need to step in and play a role. However, it would
be counter productive for those "others" to intervene in a manner
regarded by industry as antagonistic to its interests. Industry can
mount highly effective lobbying efforts to derail such efforts, even
those based on the very best intentions.
20

Gore, supra note 11 at 25-26.

21 As it turned out, that litigation was the opening salvo in massive intellectual
property litigation between Genentech and the worldwide pharmaceutical industry.
22 Gore, supra note 11 at 25-26.
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In fact, the direction of biotechnology has been set in sterile
laboratories and closed board rooms, in court chambers and politicallycharged White House meetings. 2 3 The decisions to develop ice-minus,
herbicide resistant plants, and BGH created intense public opposition to
biotechnology and lent credibility to those who argued that
biotechnology would mak6 things worse before it made them better. In
their rush to develop this new technology, companies have paid
insufficient attention to the fact that the public will involve itself
eventually in decisions affecting their communities with or without an
invitation. The public still perceives that its involvement comes well
after decisions have been made concerning product selection and
investment. It can hardly be denied that meetings held to persuade the
public to accept products such as BGH are qualitatively different from
meetings to discuss what kinds of biotechnology products could help
24
local communities and economies.
The biotechnology industry can and should do better. It ought to
be at the forefront of fostering a rational discussion of genome
technology and its implications for social policy. If such a discussion
does not begin soon, events will overtake the opportunity.
Announcements of experiments made too soon, whether successfil or
unfortunate, will catch the public's attention with the potentially
destructive consequences of fear, mistrust and backlash.
Regulatory Process
Regulation of gene transfer therapies by the FDA has been an
exercise of fitting the existing system to the new technology. Dr.
Kessler has said that while the FDA's regulatory approach may be
modified in light of additional knowledge about risks and benefits,
"[n]evertheless, early clarification of the agency's plan to apply its
existing regulatory framework to products for somatic-cell and gene
25
therapy is more prudent than waiting until the field has matured."
23 Id. at21.
24 Id. at 26-27.
and Gene Therapy by
25 David Kessler et al., Regulation of Somatic-Cell Therapy
Eng. J. Med. 1169 (1993).
New
329
Administration,
Drug
the Food and
Thus for the short term, technologies such as gene therapy will be dealt with as
drugs or biologics in the same manner as other therapies, although approval to test

gene therapies in patients has been more rigorous than any other medical area. A
synthetic polynucleotide sequence intended to alter a genetic sequence in human
somatic cels after administration to the patient is classified as a drug, so that an NDA
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The RAC reviews all proposals for NIH funded research projects
pursuant to the Guidelines. The Guidelines were intended to monitor
biotechnology research until more was known about the safety of the
organisms produced through genetic engineering. These Guidelines
have been revised over the years in a manner characterized as
demonstrating the gradual rise of technology to prominence over policy
development to the point that the RAC has "virtually relaxed itself out
'26
of a job.
The RAC responded to the recommendations of the President's
Commission in its 1982 report, Splicing Life, 27 by establishing the
Human Gene Therapy Subcommittee to review proposals involving the
use of rDNA techniques on human beings and to continue to explore
issues that would be posed by the extension of these techniques into
genetic enhancement and germline gene therapy. 2 8 The
Subcommittee has not yet addressed germline gene transfer proposals
because it lacks time. 2 9 Recent reorganization of responsibilities with
the FDA should leave it with more time to devote to such issues.
PatentOffice Process
The U.S. Patent and Trademark Office (PTO) was founded in the
age of, and evolved its rules and policies in connection with, mechanical
engineering arts. 3 0 It has struggled to accommodate biology,
traditionally considered a "soft science." Patents are supposed to
promote dissemination of knowledge; they are not designed to
safeguard public well-being. Nevertheless, the application of patent law
to biotechnology was initially subjected to ethical and legal
is required. A retroviral vector containing a gene to be administered intravenously into
the patient will be classified as a biologic, requiring a PLA and ELA (establishment
license application). A retroviral vector containing a gene and intended to modify cells
cx vivo is considered a biologic intended for further manufacture; hence, both a PLA
and ELA will be required. See 58 Fed. Reg. 53248 (1993).
26 See Gore, supra note 11 at 20.
27 President's Commission for the Study of Ethical Problems in Medicine and
Biomedical and Behavioral Research, Splicing Life: A Report on the Social and Ethical
Issues of Genetic Engineering with Human Beings.
28 Testimony of Alexander M. Capron before the Senate Committee on Labor &
Human Resources, Oct. 14, 1993, at 113.
29 See 59 Fed. Rdg. 34496 (1994) (Appendix M to NIH Guidelines).
30 William D. Noonan, Patenting Medical Technology, 11 J. Leg. Med. 263
(1990).
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controversies similar to those that delayed recognition of earlier
medical patents: Scientists debated rDNA's safety; "extremists" sued
to prevent the issuance of patents for genetically modified organisms
(GMOs); "religious leaders claimed that the sanctity of life was being
cheapened; and animal rights groups decried that animals were being
tormented." 3 1 The PTO was initially reluctant about GMOs and cells
32
on the ground that they were unpatentable "products of nature."
Perhaps the real reason was simply that they are alive.
The Supreme Court's 1980 Chakrabarty decision 3 3 caused the
PTO to implement a policy of broad patent protection for
microorganisms, plants and multicellular organisms, including
animals. 3 4 However, a decision of the Court of Appeals of the Federal
Circuit in 1987 that polyploid oysters Were patentable 3 5 was followed
shortly by a PTO notice announcing that although the Commissioner
considered "nonnaturally occurring nonhuman multicellular living
organisms, including animals, to be patentable subject matter within the
scope of 35 U.S.C. Sec 101," claims for such organisms drawn so
broadly as to potentially include human beings were regarded as
excluded from patentability due to antislavery dictates of the 13th
36
Amendment to the U.S. Constitution.
It is difficult to know what to think about this. It may be motivated
by a concern about interference with "humanness," i.e., that the
essential part of a person should not or cannot be owned by another,
and that ownership in some part of the human body will violate that
principle. Yet the patenting of implantable or implanted medical
devices do not seem to have generated the same concerns. Alternatively,
the PTO may. be agreeing with those who construe the 13th
Amendment as prohibiting the imposition of any restraint on
31 Id at 294-295.
32 Id at 295-296.
33 Diamond v. Chakrabarty, 447 U.S. 303 (1980).
34 The first patent for a genetically modified organism (GMO) issued in 1988 on a
transgenic mouse modified to be useful in studying cancer. See Noonan, supra note
29 at 297.
35 Id
36 See id. at 297.'According to patent practitioners, examiners routinely reject
claims to a transgenic mammal if the claims could include a human being. They
require that any claim directed to a non-plant multicellular organism of such scope
should include the limitation "nonhuman.'
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freedom. 37 Although it is difficult to see how a patent covering gene
therapy could interfere with a person's freedom or liberty, perhaps it
may be said that the loss of a property right in one's body or the
assignment of some type of property right to another results in a social
inferiority or subjugation in the sense that becoming property of
38
another kills what is human in us.
Does the PTO have the authority to make new policy by
introducing a constitutional limitation to patentability? May it apply
the policy differentially to different types of technology? The Supreme
Court in Chakrabarty said that Congress intended statutory subject
matter to "include anything under the sun that is made by man" and
39
that living organisms are patentable.
The PTO has generally avoided analysis of the social consequences
of inventions because the grant of a patent does not give inventors the
right to make, use or sell their inventions. On the contrary, other
agencies, the States or Congress can limit use of inventions. These other
venues are better equipped to conduct necessary fact gathering and
investigations of social consequences. The PTO has no procedures for
40
data gathering or legal analysis except with regard to patentability.
Hence, moral and ethical considerations would be explored by patent
41
examiners untrained to do so.
Jeremy Rifldn's Foundation for Economic Trends, together with a
broad coalition of mainstream religious leaders, has recently filed a
petition with the PTO to impose a moratorium on the issuance of
patents for living organisms. The petition has been described as "an idea
whose grandiose vision - to stop an entire industry in its tracks utterly belied its likely impact in the real world." On the other hand,
the reaction of the PTO and the biotechnology industry were only too
37 Current federal court decisions construe the 13th Amendment to include

prohibitions against racial discrimination, leading to speculation that it may protect
against any conduct which restricts freedom, whether imposed by government, private
individuals, or environmental conditions, the only criteria being a loss of internal
potential or social inferiority. See Robin M. Silva, Somatic Gene Therapy and the
13th Amendment: Patentability, Constitutionality, Morality 25-32 (1995)

(unpublished manuscript).
38 Id.
39 447 U.S. 309.
40 See Silva, supra note 37 at 53.
41

Id-at 57.
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predictable. The same author described the reactions by the PTO as
"dismissally out of hand;" the Biotechnology Industry Organization, as
a "clayfooted organization, which drew a 'Jesuitical' distinction between
ownership and patent monopoly;" and by BioCentury, a trade journal,
that made an effort at "explaining away this latest attack by scientific
infidels and religious philistines," as being more problematic than the
petition's criticisms because it revealed an inclination to avoid
examining the real issue that "the evolution of ethics and patent laws
that applies to patenting genes and living organisms has been haphazard
42
and largely unexamined."
Judicialand CongressionalProcess

The Supreme Court in Chakrabarty rejected the Government's
listing of potential social consequences as irrelevant to its decision and
suggested that Congress was a more suitable forum for those issues,
43
saying that:
we are without competence to entertain these arguments
either to brush them aside as fantasies generated by fear of
the unknown, or to act on them. The choice we are urged to
make is a matter of high policy for resolution with the
legislative process after the kind of investigation,
examination, and study that legislative bodies can provide
and courts cannot. That process involves the balancing of
competing values and interests, which in our democratic
system is the business of elected representatives. Whatever
their validity, the contentions now pressed on us should be
addressed to the political branches of the Government, the
Congress and the Executive, and not to the courts.
However, Congress has not effectively legislated in this area. In fact,
it has only worsened the situation by proposing amendments which
would restrict the scope of patents issuable for animals and restricting
the collection of royalties on transgenic animals4 4 and has cut PTO
45
funding. Congress seems curiously unsupportive of biotechnology.
Its proposals designed to bring regulatory order to biotechnology have
met vigorous opposition from industry and the Administration. 4 6 It
-

42 Russ Hoyle, Don't Dismiss Rifkin's Damning of Gene Patents, 13
Biotechnology 643 (1995).
43 447 U.S. 317.
44 See Noonan, supra note 30 at 318.
45 Id.
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has been my experience that it is much easier to prevent legislation than
to accomplish it. However, it may be worse if Congress does pass
legislation. Among other risks, legislation might impede research
without good reason. 47 Yet, absence of legislation has forced agencies
to retrofit existing, inadequate legislation to deal with policy issues
surrounding recombinant DNA and has slowed innovation due to
48
industrial concerns over the lack of a clear regulatory path.
Need for a National Commission
Issues raised by biotechnology in the 1980's were trivial compared
to those to be raised by genome technology. To resolve those issues
effectively and fairly, we must develop a coherent moral and ethical
basis for decisions in several areas, including patent and FDA law.
Neither the FDA nor the RAC has even begun to address the
questions which will be raised by genome technology. They have
attempted only to fit somatic cell gene therapy within the existing
regulatory framework. 4 9 Nor can existing patent law answer such
questions as how to clearly and concisely describe a living creature
sufficiently to meet the enabling requirement, what scope of
enforcement would apply to potentially infringing organisms or nucleic
50
acid sequences or questions of ownership of biological materials.
And if patentability is to turn on whether an invention claims a human
body part, how does the PTO go about addressing the question of
what it is that makes up personhood? If one has a plastic replacement
part, does it make one a different person? Is that part personal property
or something else? Does one cease to be human if it is not the original
version or if someone else has a property right to a body part? Is the
body indivisible from that which makes personhood?
The President's Commission addressed genetic manipulation and
noted concerns about the possibility of self-perpetuating "mistakes," a
concern that stems from the fact that hybrid life forms may be able to
reproduce themselves, especially animal-human hybrids. This raises the
46 See Gore, supranote 11 at 26-27.

47 See OTA, supra.note 17 at 16.
48 See Gore, supra note 11 at 26-27.

49 See supra note 25 and accompanying text.
50 See Noonan, supra note 29 at 299.
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question of which characteristics are uniquely human and whether the
wrong lies in bestowing some but not all of those characteristics on the
new creation or in denying purely human makeup to the being that
might otherwise have resulted from the human genetic material. The
51
possibility that some aspect. of humanness might be changed:
rightly evokes profound concerns and burdens everyone
with an awesome and inescapable responsibility - either to
develop and employ this capability for the good of
humanity or to reject it in order to avoid potential
undesirable consequences.
Thus far, the RAC has served as a surrogate for a national
commission on bioethics. But it is not enough. Professor Capron has
called for establishing a new commission on bioethical issues to
encourage interdisciplinary participation, provide public authority for
its statements and permit scholarly consideration required for this
subject matter. 52 In his vision, the commission could serve as a catalyst
to force a closer look at ways that health care decisions have
traditionally been made; forum to air differences, articulate broad
areas of existing agreement, and reassure those forced to make
bioethical decisions such as patients, professionals and public servants as well as a important player in engendering and encouraging the
process by which a vibrant and ever-developing society reexamines,
53
revises and reaffirms its system of values and beliefs.
Professor Capron correctly proposes that a national commission
begin as soon as possible. He points out that it should be federal
because issues transcend state borders. Acknowledging that some
decisions will be made by courts, he correctly observes that courts look
to legislatures for guidance. While legislation will be needed, demands
on legislative bodies are already overwhelming, and their inherently
political atmosphere risks polarization despite large likely agreement.
54
Also, administrative bodies, too, are already overtaxed.

51
52
53
54

President's Commission, supra note 27 at 53-70.
See Capron, supra note 28 at 111-113.
Id.
Id.
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Conclusion
I close with an excerpt from the 1938 C. S. Lewis novel, Out of the
Silent Planet. 5 5 Outspoken in his criticism of science and English
society in the early 20th Century, Lewis' book deals with efforts to
colonize Mars.
This comes from a scene in which the hero is traveling with an
56
intelligent Martian.
Then, as his hunger ebbed, the sense of his situation
returned with dismaying force. The huge, seal-like creature
seated beside him became unbearably ominous. It seemed
friendly; but it was very big, very black, and he knew
nothing at all about it. ... And was it really as rational as it
appeared?
It was only many days later that Ransom discovered
how to deal with these sudden losses of confidence. They
arose when the rationality of the hross tempted you to think
of it as a man. Then it became abominable - a man seven
feet high, with a snaky body, covered, face and all, with
thick black animal hair, and whiskered like a cat. But
starting from the other end you had an animal with
everything an animal ought to have - glossy coat, liquid
eye, sweet breath and whitest teeth -and added to all
these, as though Paradise had never been lost and earliest
dreams were true, the charm of speech and reason. Nothing
could be more than disgusting the one impression; nothing
more delightful than the other. It all depended on the point
of view.

55 Reprinted by Easton Press, 1994.
56 Id. Ch. 8.

